Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

NCT01445769 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Post-Essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Ruxolitinib

Sponsor

Incyte Corporation